By Sian Lazell
August 11, 2016
Boehringer Ingelheim Vetmedica (BIVI) has launched a new combination vaccine for cats in the US.
Ultra Hybrid FVRCP is a non-adjuvanted vaccine indicated as an aid in prevention of disease caused by feline herpesvirus (viral rhinotracheitis), calicivirus infection and panleukopenia (distemper) in cats and kittens aged eight weeks and older.
BIVI said Ultra Hybrid FVRCP is the only combination vaccine with dual strain calicivirus shown to provide broad spectrum cross-neutralization of field isolates of feline calicivirus.
Feline calicivirus is highly contagious and is one of the major causes of upper respiratory infections or cat flu in cats.
"The term 'hybrid' refers to the combination of inactivated dual-strain calicivirus with a modified live feline panleukopenia and herpesvirus in one non-adjuvanted, reduced-volume vaccine," said Arne Zislin, veterinary technical manager at BIVI.
"What makes this product unique is that Ultra Hybrid FVRCP is a non-adjuvanted feline core vaccine that contains both inactivated and modified-live fractions for the most diverse protection available in a 0.5 mL vaccine."
BIVI explained low volume vaccines such as Ultra Hybrid FVRCP make administration less stressful for animals. Ultra Hybrid FVRCP uses PureFil technology which is designed to decrease vaccine reactions by reducing extraneous proteins and cellular debris.
Marty Becker, founder of the Fear Free initiative which promotes approach and control techniques for less stressful veterinary clinic visits for pets, added: "Because of its unique formulation and resulting potential to provide a more comfortable vaccine experience, as well as less vaccine injected over the lifetime of the pet, Ultra Hybrid FVRCP is an ideal addition to the tools available to veterinarians to provide a fear-free clinic experience."
The vaccine also has a label with a three-part design that enables veterinarians and owners to track which vaccines the pet has received in the clinic and at home. BIVI said Ultra Hybrid FVRCP is its first vaccine to have the feature.
German firm Boehringer Ingelheim's Vetmedica branch is headquartered in St Joseph, Missouri. The unit is focused on developing products for the swine, cattle, equine and companion animal markets.
Ahead of its merger with Merial, Boehringer agreed to divest its US companion animal and rabies vaccine portfolioas a prerequisite of antitrust regulations. The portfolio includes its other cat vaccines Fel-O-Vax, Ultra Fel-O-Vax and Fel-O-Guard, which were acquired by Boehringer from Fort Dodge Animal Health in 2009.
Boehringer claims the Ultra Fel-O-Vax line is the first 0.5ml feline vaccine line designed to offer a more comfortable vaccine administration, with 50% less volume than most vaccines. Reprinted with permission of Animal Pharm News